ALECENSA Drug Patent Profile

When do Alecensa patents expire, and when can generic versions of Alecensa launch?

Alecensa is a drug marketed by Hoffmann-la Roche and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-three patent family members in thirty-nine countries.

The generic ingredient in ALECENSA is alectinib hydrochloride. One supplier is listed for this compound. Additional details are available on the alectinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Alecensa

Alecensa was eligible for patent challenges on December 11, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 24, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ALECENSA

International Patents:	143
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	23
Patent Applications:	3,073
Drug Prices:	Drug price information for ALECENSA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALECENSA
What excipients (inactive ingredients) are in ALECENSA?	ALECENSA excipients list
DailyMed Link:	ALECENSA at DailyMed

See drug prices for ALECENSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ALECENSA

Constraining patent/regulatory exclusivity:

11,433,076

NDA:

208434

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALECENSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Phase 2/Phase 3
University of Birmingham	Phase 2/Phase 3
Cancer Research UK	Phase 2/Phase 3

See all ALECENSA clinical trials

Pharmacology for ALECENSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors

Paragraph IV (Patent) Challenges for ALECENSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ALECENSA	Capsules	alectinib hydrochloride	150 mg	208434	1	2019-12-11

US Patents and Regulatory Information for ALECENSA

ALECENSA is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,433,076.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann-la Roche	ALECENSA	alectinib hydrochloride	CAPSULE;ORAL	208434-001	Dec 11, 2015		RX	Yes	Yes	10,350,214		Y
Hoffmann-la Roche	ALECENSA	alectinib hydrochloride	CAPSULE;ORAL	208434-001	Dec 11, 2015		RX	Yes	Yes
Hoffmann-la Roche	ALECENSA	alectinib hydrochloride	CAPSULE;ORAL	208434-001	Dec 11, 2015		RX	Yes	Yes	9,440,922		Y
Hoffmann-la Roche	ALECENSA	alectinib hydrochloride	CAPSULE;ORAL	208434-001	Dec 11, 2015		RX	Yes	Yes	11,433,076		Y

International Patents for ALECENSA

When does loss-of-exclusivity occur for ALECENSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Malaysia

Mexico

New Zealand

Poland

Russian Federation

Singapore

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ALECENSA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	100187
Argentina	132148
Australia	2015250574
Australia	2020230293

Supplementary Protection Certificates for ALECENSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2441753	300876	Netherlands		PRODUCT NAME: ALECTINIB DAN WEL EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1169/001 20170220
2441753	CA 2017 00024	Denmark		PRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/16/1169/01 20170220
2441753	PA2017017	Lithuania		PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
2441753	122017000048	Germany		PRODUCT NAME: ALECTINIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/16/1169 20170216

ALECENSA (alectinib) market dynamics and financial trajectory: exclusivity, competitive threats, and revenue exposure

Last updated: June 23, 2026

Alecesa (alectinib) is an FDA-approved ALK inhibitor with a revenue profile driven by US adoption, subsequent label expansion, and a slower shift to lower-cost competition than many small-molecule oncology drugs because the company’s value is supported by strong clinical positioning and a defensible patent landscape into the late-2020s/early-2030s (depending on jurisdiction and specific IP layers). The financial trajectory is tied to: (1) launch-and-upcurve dynamics in newly diagnosed metastatic ALK-positive NSCLC, (2) conversion from next-line use to earlier-line use after label expansions, (3) formulary and channel coverage in the US, and (4) the timing and intensity of ALK-competitive erosion from next-gen ALK inhibitors and generics/biosimilars risk where relevant.

What drives Alecensa (alectinib) revenue growth and market share across ALK-positive NSCLC?

Primary revenue drivers

1. Line-of-therapy placement and guideline adoption
   Revenue scales with penetration into first-line and later-line treatment settings where clinical outcomes and tolerability support preference over older ALK inhibitors and some competing agents.

2. US formulary and reimbursement dynamics
   Commercial performance depends on payer coverage, prior authorization patterns, and ongoing price concessions. Oncology pricing typically tracks a mix of WAC discipline and managed-entry agreements, with net price influenced by rebates.

3. Patient access and persistence
   The drug’s value in ALK-positive metastatic NSCLC is linked to tolerability and dose-management outcomes. Persistence affects cumulative treatment duration and therefore revenue per treated patient.

4. Competitive positioning versus other ALK inhibitors
   In the ALK inhibitor class, market share is influenced by head-to-head or cross-trial efficacy interpretations (progression-free survival), CNS activity, and overall safety profile. Sales typically rise when clinicians view the drug as default first-line or dominant second-line option.

Secondary drivers

• Geographic rollout speed outside the US
• Clinical trial read-through that expands perceived utility in specific subgroups
• Site-of-care contracting and oncology center-of-excellence prescribing patterns

How is Alecensa (alectinib) positioned versus competing ALK inhibitors and what does that mean for pricing pressure?

Competitive set (ALK inhibitors)

• Next-generation ALK inhibitors with strong CNS penetration and dosing convenience influence switching behavior.
• Where competing agents have stronger perceived OS signals or label advantages (for example, specific patient subsets, resistance profiles, or CNS disease), competitive pressure increases and net pricing tends to soften.

What “competitive erosion” looks like in practice

• Managed switching: payers or pharmacy benefit managers steer patients to preferred agents through tiering or prior authorization criteria.
• Net price compression: even without immediate share loss, rebate pressure can reduce revenue per unit.
• Channel mix: shifts between hospital outpatient vs specialty pharmacy can change realized margins.

Implication for Alecensa

• The product’s revenue durability is typically strongest when it maintains “default” status in the largest spend segment, usually first-line metastatic ALK-positive NSCLC, and when it is not displaced by a superior value proposition on payer decision frameworks.

When does Alecensa (alectinib) lose exclusivity, and what layers of IP matter for market entry risk?

Exclusivity risk framework (US) Alecesa’s market entry risk is not a single date event. It is a stack of:

• Patent expiration for active ingredient and key composition/usage claims
• Regulatory exclusivity tied to New Molecular Entity (NME) or other statutory protections
• Formulation and method-of-use patents that can block generic equivalents even after earlier patents end
• Orange Book activity that identifies any listed patents likely to trigger Hatch-Waxman litigation

Key commercial reality

• In oncology small molecules, generic entry often requires a long runway of patent clearance. The drug’s revenue protection usually persists until the last relevant formulation or method-of-use patent not only expires but also clears via settlement or final court outcomes.

What patents protect Alecensa (alectinib) and how many patent “layers” block generic entry?

A defensible patent estate for alectinib products typically includes multiple categories:

• Composition of matter (active ingredient and salts/polymorphs)
• Pharmaceutical compositions (formulations, excipient systems, particle size, release characteristics)
• Methods of treatment (ALK-positive NSCLC, line-of-therapy, dosing regimens)
• Combination or resistance-related claims (when present)
• Manufacturing method claims (less common for entry blocking but relevant for process design)

Market impact of multi-layer estates

• Generic challengers generally target the narrowest patent set possible to accelerate entry. If the estate includes broad method-of-use coverage, “at-risk” entry becomes delayed or requires design-around that may not succeed.

What is the Orange Book status of Alecensa (alectinib) and how many listed patents are active?

Orange Book status is the practical map of litigation risk because it lists patents for FDA approval actions. The key decision variables for paragraph IV risk are:

• Count of Orange Book-listed patents
• Patent types (drug substance vs drug product vs method-of-use)
• Whether any patents have litigation history or consent judgments

Commercial inference

• A higher count of listed patents with staggered expirations typically correlates with delayed generic entry and a longer window of price and margin protection.

What generic entry risks exist for Alecensa (alectinib) under Paragraph IV, and how do settlement patterns usually affect launch timing?

Paragraph IV risk mechanics

• Generic applicants file certification against Orange Book patents (or are required to do so).
• If any listed patents are challenged, brand sponsors often sue, triggering the 30-month stay (subject to specific procedural outcomes).

Settlement outcomes

• Settlements can convert litigation into an agreed “carve-out” or date-based entry schedule.
• Even if patents are not fully invalidated, settlements often reduce uncertainty and force later launch windows.

Market consequence

• Alecensa’s financial trajectory is likely more sensitive to settlement-driven entry dates than to final court decisions alone because settlements determine actual dosing availability in the channel.

How does Alecensa (alectinib) compare with Brigatinib (ALUNBRIG) on revenue durability and competitive switching risk?

Cross-drug dynamic

• Both are ALK inhibitors with clinically differentiated profiles.
• Revenue durability is driven by: (1) relative label fit in first-line vs later-line segments, (2) payer preference, (3) discontinuation rates due to tolerability, and (4) speed of guideline adoption.

Switching risk signals

• Rapid payer adoption of one agent can force volume migration even when clinical differences are marginal for certain subgroups.
• Net price gaps, rather than WAC, often determine who wins the contracting process.

For Alecensa

• If Alecensa is preferred on value frameworks and maintains persistence, its erosion curve tends to be slower. If payer formularies shift, it can accelerate as oncology dosing is chronic until progression.

What litigation and FDA regulatory events affect Alecensa (alectinib) market access and launch timing?

Litigation channels that matter for commercial outcomes

• Patent infringement suits tied to ANDA filings
• Consent judgments or settlement agreements that establish entry dates
• FDA label or manufacturing changes that alter the product’s defensibility

FDA regulatory dynamics

• Changes to indications, dosing schedules, or combination regimens can shift the patent landscape by activating new method-of-use claims.
• Safety label updates can affect prescribing behavior and persistence, altering unit sales.

How does manufacturing and supply stability influence Alecensa (alectinib) sales and margins during competitive pressure?

Oncology small molecules often face:

• Supply chain constraints that can create short-term revenue spikes in contracted channels
• Later normalization that reduces premium pricing
• Cost inflation in APIs and intermediates affecting gross margin

Margin mechanics

• Net revenue is sensitive to rebate structures and contract pricing.
• Gross margin is sensitive to API costs, yield, and batch success rates.

Financial trajectory: what milestones should investors and strategics track for Alecensa (alectinib)?

Quarterly and annual KPI set

1. US growth rate in ALK-positive NSCLC using specialty pharmacy and hospital outpatient channels
2. Net revenue vs gross-to-net trend (rebates, discounts)
3. Trend in new patient starts and persistence duration
4. Competitor displacement indicators (formulary wins, switch rates)
5. Operating expense leverage for the brand and lifecycle management

How to interpret inflection points

• Label expansions tend to produce step-ups after payer coverage stabilizes.
• Competitive entry tends to show initial share stability followed by net price compression if contract leverage shifts.

Key commercial timeline: exclusivity, patent expiry, and generic threat windows for Alecensa

A reliable timeline requires Orange Book and specific patent expiration dates and any associated litigation. Without the underlying list and docket outcomes, the only accurate statement is structural: generic launch risk in the US is typically concentrated in windows created by the expiration of the last relevant Orange Book-listed patent(s), with entry often deferred by litigation stays or settlements.

Key Takeaways

• Alecensa’s market dynamics are driven by its ALK-positive metastatic NSCLC positioning, payer contracting, and persistence through tolerability and dosing management.
• Financial trajectory typically tracks guideline placement and payer preference more than it tracks pure WAC pricing.
• Generic entry risk is governed by a multi-layer IP stack, reflected in Orange Book patent listings and Hatch-Waxman litigation dynamics, not a single exclusivity end date.
• Competitive erosion in ALK inhibitors often shows up first as net price pressure and channel preference shifts before a major unit decline.
• The decisive commercial variable for future financial performance is the timing of any granted entry paths for generics or authorized competitors, which is usually shaped by patent expiration plus settlement-driven launch dates.

FAQs

1. How does first-line label positioning for alectinib affect long-term revenue retention versus second-line-only ALK inhibitors?
2. What do Orange Book patent categories (drug substance vs drug product vs method-of-use) typically imply for generic launch delay?
3. How does gross-to-net movement for oncology brands signal payer tightening even when unit sales stay stable?
4. What litigation timelines (30-month stays, consent judgments) most often determine actual generic entry dates for small-molecule oncology drugs?
5. How do contracting and specialty pharmacy channel shifts change net margin for oral oncology therapies like alecensa?

References

1. FDA. Approved Drug Products with Therapeutapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. FDA. Hatch-Waxman Act and Paragraph IV Certification Overview. U.S. Food and Drug Administration.
3. Leyton Tech. US FDA drug approvals and regulatory history for alecensa (alectinib). Leyton Tech.

DrugChatter Q&A for ALECENSA

Can Alecensa be used for ALK-positive lung cancer?